A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 7-Day Safety and Tolerability Study of Denufosol Tetrasodium Inhalation Solution Administered Via PARI LC Star in Patients 2 to 4 Years of Age With Cystic Fibrosis

Trial Profile

A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 7-Day Safety and Tolerability Study of Denufosol Tetrasodium Inhalation Solution Administered Via PARI LC Star in Patients 2 to 4 Years of Age With Cystic Fibrosis

Completed
Phase of Trial: Phase II

Latest Information Update: 30 May 2014

At a glance

  • Drugs Denufosol (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions
  • Acronyms REACH-1
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 30 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top